RESUMEN
Cefuroxime pharmacokinetic profile was investigated in 6 Beagle dogs after single intravenous, intramuscular, and subcutaneous administration at a dosage of 20 mg/kg. Blood samples were withdrawn at predetermined times over a 12-h period. Cefuroxime plasma concentrations were determined by HPLC. Data were analyzed by compartmental analysis. Peak plasma concentration (Cmax ), time-to-peak plasma concentration (Tmax ), and bioavailability for the intramuscular and subcutaneous administration were (mean ± SD) 22.99 ± 7.87 µg/mL, 0.43 ± 0.20 h, and 79.70 ± 14.43% and 15.37 ± 3.07 µg/mL, 0.99 ± 0.10 h, and 77.22 ± 21.41%, respectively. Elimination half-lives and mean residence time for the intravenous, intramuscular, and subcutaneous administration were 1.12 ± 0.19 h and 1.49 ± 0.21 h; 1.13 ± 0.13 and 1.79 ± 0.24 h; and 1.04 ± 0.23 h and 2.21 ± 0.23 h, respectively. Significant differences were found between routes for Ka , MAT, Cmax , Tmax , t½(a) , and MRT. T > MIC = 50%, considering a MIC of 1 µg/mL, was 11 h for intravenous and intramuscular administration and 12 h for the subcutaneous route. When a MIC of 4 µg/mL is considered, T > MIC = 50% for intramuscular and subcutaneous administration was estimated in 8 h.
Asunto(s)
Antibacterianos/farmacocinética , Cefuroxima/farmacocinética , Perros/sangre , Animales , Antibacterianos/administración & dosificación , Antibacterianos/sangre , Área Bajo la Curva , Disponibilidad Biológica , Cefuroxima/administración & dosificación , Cefuroxima/sangre , Estudios Cruzados , Vías de Administración de Medicamentos , Femenino , Semivida , MasculinoRESUMEN
Antimicrobial agents are essential tools for treating and controlling bacterial infections in poultry production. Veterinarians have a huge responsibility when using antimicrobials in poultry producing meat and eggs for human consumption. The term 'judicious use' of antimicrobials implies the optimal selection of drug, dose and duration of antimicrobial treatment, along with a reduction in inappropriate and excessive use as a means of slowing the emergence of antimicrobial resistance. The proper use of antimicrobials depends on the knowledge of interrelationships between bacteria, antimicrobial, host and consumer. This article reviews the anatomical-physiological features of poultry relating to drug disposition as well as the pharmacological and therapeutic characteristics of the most commonly used antimicrobials in broiler chickens. Doses frequently employed for flock treatment are presented as are accepted withdrawal times.
Asunto(s)
Antiinfecciosos/uso terapéutico , Pollos , Enfermedades de las Aves de Corral/tratamiento farmacológico , Animales , HumanosRESUMEN
The pharmacokinetic properties and bone concentrations of lincomycin in cats after single intravenous and intramuscular administrations at a dosage rate of 10 mg/kg were investigated. Lincomycin minimum inhibitory concentration (MIC) for some gram-positive strains isolated from clinical cases was determined. Serum lincomycin disposition was best-fitted to a bicompartmental and a monocompartmental open models with first-order elimination after intravenous and intramuscular dosing, respectively. After intravenous administration, distribution was rapid (T(1/2(d)) = 0.22 ± 0.09 h) and wide as reflected by the volume of distribution (V((d(ss)))) of 1.24 ± 0.08 L/kg. Plasma clearance was 0.28 ± 0.09 L/h · kg and elimination half-life (T(1/2)) 3.56 ± 0.62 h. Peak serum concentration (C(max)), T(max), and bioavailability for the intramuscular administration were 7.97 ± 2.31 µg/mL, 0.12 ± 0.05 h, and 82.55 ± 23.64%, respectively. Thirty to 45 min after intravenous administration, lincomycin bone concentrations were 9.31 ± 1.75 µg/mL. At the same time after intramuscular administration, bone concentrations were 3.53 ± 0.28 µg/mL. The corresponding bone/serum ratios were 0.77 ± 0.04 (intravenous) and 0.69 ± 0.18 (intramuscular). Lincomycin MIC for Staphylococcus spp. ranged from 0.25 to 16 µg/mL and for Streptococcus spp. from 0.25 to 8 µg/mL.
Asunto(s)
Antibacterianos/administración & dosificación , Antibacterianos/farmacocinética , Huesos/metabolismo , Gatos/sangre , Lincomicina/administración & dosificación , Lincomicina/farmacocinética , Animales , Antibacterianos/sangre , Antibacterianos/metabolismo , Área Bajo la Curva , Disponibilidad Biológica , Femenino , Semivida , Inyecciones Intramusculares , Inyecciones Intravenosas , Lincomicina/sangre , Lincomicina/metabolismo , MasculinoRESUMEN
The pharmacokinetic profile and bioavailability of a long-acting formulation of cephalexin after intramuscular administration to cats was investigated. Single intravenous (cephalexin lysine salt) and intramuscular (20% cephalexin monohydrate suspension) were administered to five cats at a dose rate of 10 mg/kg. Serum disposition curves were analyzed by noncompartmental approaches. After intravenous administration, volume of distribution (V(z)), total body clearance (Cl(t)), elimination constant (λ(z)), elimination half-life (t(½)(λ)) and mean residence time (MRT) were: 0.33±0.03 L/kg; 0.14±0.02 L/hkg, 0.42±0.05 h(-1), 1.68±0.20 h and 2.11±0.25 h, respectively. Peak serum concentration (C(max)), time to peak serum concentration (T(max)) and bioavailability after intramuscular administration were 15.67±1.95 µg/mL, 2.00±0.61 h and 83.33±8.74%, respectively.
Asunto(s)
Antibacterianos/farmacocinética , Cefalexina/farmacocinética , Animales , Antibacterianos/administración & dosificación , Antibacterianos/sangre , Disponibilidad Biológica , Gatos , Cefalexina/administración & dosificación , Cefalexina/sangre , Preparaciones de Acción Retardada/administración & dosificación , Preparaciones de Acción Retardada/farmacocinética , Inyecciones Intramusculares/veterinaria , Inyecciones Intravenosas/veterinariaRESUMEN
In a four-period, cross-over study, the fluoroquinolone antibacterial drug marbofloxacin (MB) was administered to calves, alone and in combination with the nonsteroidal anti-inflammatory drug tolfenamic acid (TA). Both drugs were administered intramuscularly (IM) at doses of 2 mg/kg. A tissue cage model of inflammation, based on the actions of the mild irritant carrageenan, was used to evaluate the pharmacokinetics (PK) of MB and MB in combination with TA. MB mean values of area under concentration-time curve (AUC) were 15.1 µg·h/mL for serum, 12.1 µg·h/mL for inflamed tissue cage fluid (exudate) and 9.6 µg·h/mL for noninflamed tissue cage fluid (transudate). Values of C(max) were 1.84, 0.35 and 0.31 µg/mL, respectively, for serum, exudate and transudate. Mean residence time (MRT) of 23.6 h (exudate) and 22.6 h (transudate) also differed significantly from serum MRT (8.6 h). Co-administration of TA did not affect the PK profile of MB. The pharmacodynamics of MB was investigated using a bovine strain of Mannheimia haemolytica. Time-kill curves were established ex vivo on serum, exudate and transudate samples. Modelling the ex vivo serum time-kill data to the sigmoid E(max) equation provided AUC(24 h) /MIC values required for bacteriostatic (18.3 h) and bactericidal actions (92 h) of MB and for virtual eradication of the organism was 139 h. Corresponding values for MB + TA were 20.1, 69 and 106 h. These data were used to predict once daily dosage schedules for a bactericidal action, assuming a MIC(90) value of 0.24 µg/mL, a dose of 2.6 mg/kg for MB and 2.19 mg/kg for MB + TA were determined, which are similar to the currently recommended dose of 2.0 mg/kg.
Asunto(s)
Antibacterianos/farmacocinética , Antiinflamatorios no Esteroideos/farmacocinética , Bovinos/metabolismo , Fluoroquinolonas/farmacocinética , ortoaminobenzoatos/farmacocinética , Animales , Antibacterianos/administración & dosificación , Antibacterianos/farmacología , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/farmacología , Cromatografía Líquida de Alta Presión/veterinaria , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Esquema de Medicación/veterinaria , Quimioterapia Combinada/veterinaria , Fluoroquinolonas/administración & dosificación , Fluoroquinolonas/farmacología , Inyecciones Intramusculares/veterinaria , Masculino , Mannheimia haemolytica/efectos de los fármacos , Pruebas de Sensibilidad Microbiana/veterinaria , Distribución Aleatoria , ortoaminobenzoatos/administración & dosificación , ortoaminobenzoatos/farmacologíaRESUMEN
The aim of this study was to characterise the pharmacokinetic properties of different formulations of erythromycin in cats. Erythromycin was administered as lactobionate (4 mg/kg intravenously (IV)), base (10mg/kg, intramuscularly (IM)) and ethylsuccinate tablets or suspension (15 mg/kg orally (PO)). After IV administration, the major pharmacokinetic parameters were (mean ± SD): area under the curve (AUC)((0-∞)) 2.61 ± 1.52 microgh/mL; volume of distribution (V(z)) 2.34 ± 1.76L/kg; total body clearance (Cl(t)) 2.1 0 ± 1.37 L/hkg; elimination half-life (t(½)(λ)) 0.75 ± 0.09 h and mean residence time (MRT) 0.88 ± 0.13 h. After IM administration, the principal pharmacokinetic parameters were (mean ± DS): peak concentration (C(max)), 3.54 ± 2.16 microg/mL; time of peak (T(max)), 1.22 ± 0.67 h; t(½)(λ), 1.94 ± 0.21 h and MRT, 3.50 ± 0.82 h. The administration of erythromycin ethylsuccinate (tablets and suspension) did not result in measurable serum concentrations. After IM and IV administrations, erythromycin serum concentrations were above minimum inhibitory concentration (MIC)(90)=0.5 microg/mL for 7 and 1.5h, respectively. However, these results should be interpreted cautiously since tissue erythromycin concentrations have not been measured and can reach much higher concentrations than in blood, which may be associated with enhanced clinical efficacy.
Asunto(s)
Antibacterianos/administración & dosificación , Antibacterianos/farmacocinética , Eritromicina/administración & dosificación , Eritromicina/farmacocinética , Administración Oral , Animales , Antibacterianos/sangre , Área Bajo la Curva , Enfermedades de los Gatos/tratamiento farmacológico , Gatos/sangre , Eritromicina/sangre , Femenino , Semivida , Inyecciones Intramusculares/veterinaria , Inyecciones Intravenosas/veterinaria , Masculino , Tasa de Depuración MetabólicaAsunto(s)
Antibacterianos/farmacología , Gatos/metabolismo , Cefoxitina/farmacocinética , Animales , Antibacterianos/administración & dosificación , Antibacterianos/sangre , Gatos/sangre , Cefoxitina/administración & dosificación , Cefoxitina/sangre , Inyecciones Intramusculares/veterinaria , Inyecciones Intravenosas/veterinariaRESUMEN
Twelve healthy horses were subject to the monoioidoacetate (MIA) carpitis model, which was allowed to develop for 7 days. The horses were then randomly divided into two groups. Group A (control) received an intramuscular injection of normal saline every 4 days for a total of seven injections while group B received 500 mg of a PSGAG (SYNTEX CSY36) intramuscularly every 4 days for seven treatments. Efficacy of the PSGAG was evaluated by three clinical outcomes: lameness score, carpal circumference and maximum carpal flexion. Clinical outcomes were measured on days -8 (previous to carpitis induction), 0 (previous to drug treatment), 7, 14, 21, 28 and 35. Areas under the curve clinical outcome as function of time were built and used as variables for the statistical analysis. There was less joint circumference enlargement and lameness and greater carpal flexion in PSGAG-treated horses compared with that in controls. The studied compound has demonstrated to be efficacious on the treatment of a chemically induced carpitis in horses.
Asunto(s)
Artritis/veterinaria , Articulaciones del Carpo/efectos de los fármacos , Glicosaminoglicanos/uso terapéutico , Enfermedades de los Caballos/tratamiento farmacológico , Cojera Animal/tratamiento farmacológico , Animales , Artritis/tratamiento farmacológico , Articulaciones del Carpo/patología , Modelos Animales de Enfermedad , Glicosaminoglicanos/administración & dosificación , Glicosaminoglicanos/normas , Enfermedades de los Caballos/patología , Caballos , Inyecciones Intramusculares/veterinaria , Resultado del TratamientoRESUMEN
In a four-period cross-over study, the fluoroquinolone antibacterial drug marbofloxacin (MB) was administered to goats intramuscularly (IM) at a dose rate of 2 mg/kg, both alone and in combination with the non-steroidal anti-inflammatory drug tolfenamic acid (TA), also administered IM at a dose rate of 2 mg/kg. Using a tissue cage model of inflammation, based on the irritant actions of carrageenan, the pharmacokinetics (PK) of MB and MB in combination with TA were determined. MB mean values of area under concentration-time curve (AUC) were similar for serum (5.60 microg h/mL), inflamed tissue cage fluid (exudate; 5.32 microg h/mL) and non-inflamed tissue cage fluid (transudate; 4.82 microg h/mL). Values of mean residence time (MRT) of MB in exudate (15.5 h) and transudate (15.8 h) differed significantly from serum MRT (4.23 h). Co-administration of TA did not affect the PK profile of MB. The pharmacodynamics of MB were investigated using a caprine strain of Mannheimia haemolytica. Integration of PK data with ex vivo bacterial time-kill curve data for serum, exudate and transudate provided AUC(24h)/minimum inhibitory concentration (MIC) ratios of 160, 133 and 121 h, respectively, for the strain of organism used. Modelling of the ex vivo time-kill data to the sigmoid E(max) equation provided AUC(24h)/MIC values required for bacteriostatic and bactericidal actions of MB and for virtual eradication of the organism of 27.6, 96.2 and 147.3 h, respectively. Corresponding values for MB+TA were 20.5, 66.5 and 103.0 h. These data were used to predict once daily dosage schedules of MB for subsequent clinical evaluation.
Asunto(s)
Fluoroquinolonas/farmacocinética , Cabras/metabolismo , Mannheimia haemolytica/efectos de los fármacos , ortoaminobenzoatos/farmacocinética , Animales , Antibacterianos/administración & dosificación , Antibacterianos/farmacocinética , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/farmacocinética , Área Bajo la Curva , Relación Dosis-Respuesta a Droga , Combinación de Medicamentos , Femenino , Fluoroquinolonas/administración & dosificación , Enfermedades de las Cabras/tratamiento farmacológico , Cabras/sangre , Inyecciones Intramusculares/veterinaria , Mannheimia haemolytica/crecimiento & desarrollo , Pruebas de Sensibilidad Microbiana , Modelos Biológicos , Infecciones por Pasteurellaceae/tratamiento farmacológico , Infecciones por Pasteurellaceae/veterinaria , ortoaminobenzoatos/administración & dosificaciónRESUMEN
The fluoroquinolone antimicrobial drug, marbofloxacin, was administered intravenously (IV) and intramuscularly (IM) to sheep at a dose rate of 2 mg kg(-1) in a 2-period cross-over study. Using a tissue cage model of inflammation, the pharmacokinetic properties of marbofloxacin were established for serum, inflamed tissue cage fluid (exudate) and non-inflamed tissue cage fluid (transudate). For serum, after IV dosing, mean values for pharmacokinetic parameters were: clearance 0.48 L kg(-1) h(-1); elimination half-life 3.96 h and volumes of distribution 2.77 and 1.96 L kg(-1), respectively, for V(darea) and V(ss). After IM dosing mean values for pharmacokinetic variables were: absorption half-time 0.112 h, time of maximum concentration 0.57 h, terminal half-life (T(1/2)el) 3.65 h and bioavailability 106%. For exudate, mean T(1/2)el values were 12.38 and 13.25 h, respectively, after IV and IM dosing and for transudate means were 13.39 h (IV) and 12.55 h (IM). The in vitro minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) and ex vivo time-kill curves for marbofloxacin in serum, exudate and transudate were established against a pathogenic strain of Mannheimia haemolytica. Integration of in vivo pharmacokinetic data with MIC determined in vitro provided mean values of area under curve (AUC)/MIC ratio for serum, exudate and transudate of 120.2, 156.0 and 156.6 h after IV dosing and 135.5, 165.3 and 146.2 h after IM dosing, respectively. After IM administration maximum concentration (C(max))/MIC ratios were 21.1, 6.76 and 5.91, respectively, for serum, exudate and transudate. The ex vivo growth inhibition data after IM administration were fitted to the sigmoid E(max) (Hill) equation to provide values for serum of AUC(24h)/MIC producing, bactericidal activity (22.51 h) and virtual eradication of bacteria (35.31 h). It is proposed that these findings might be used with MIC(50) or MIC(90) data to provide a rational approach to the design of dosage schedules which optimise efficacy in respect of bacteriological as well as clinical cures.
Asunto(s)
Antiinfecciosos/farmacología , Fluoroquinolonas/farmacocinética , Ovinos/metabolismo , Animales , Antiinfecciosos/administración & dosificación , Antiinfecciosos/uso terapéutico , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Fluoroquinolonas/administración & dosificación , Fluoroquinolonas/uso terapéutico , Inyecciones Intramusculares/veterinaria , Inyecciones Intravenosas/veterinaria , Mannheimia haemolytica/efectos de los fármacos , Tasa de Depuración Metabólica , Pruebas de Sensibilidad Microbiana , Infecciones por Pasteurellaceae/tratamiento farmacológico , Infecciones por Pasteurellaceae/veterinaria , Enfermedades de las Ovejas/tratamiento farmacológico , Enfermedades de las Ovejas/microbiologíaRESUMEN
Diclofenac is a hydrophilic non-steroidal anti-inflammatory drug widely used in humans and animals. Previous reports have shown that this compound has low percutaneous absorption in horses. The effect of five penetration enhancers (10% urea, 15% and 20% oleic acid and 5% and 10% d-limonene) on the percutaneous absorption of diclofenac diethylamine through horse skin was evaluated in vitro using Franz-type diffusion cells. All tested penetration enhancers induced a significant increase in diclofenac diethylamine permeation, with limonene showing the highest enhancing effect at the lowest concentration (5%) applied. The presence of the permeation enhancers did not affect lag-time. This is the first in vitro study of the effects of penetration enhancers on transdermal permeation of diclofenac diethylamine across horse skin. The results suggested that urea, limonene and 5% oleic acid were useful for enhancing the transdermal absorption of diclofenac diethylamine and may assist in the development of a transdermal formulation of diclofenac diethylamine for use in horses.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacocinética , Diclofenaco/farmacocinética , Caballos/metabolismo , Absorción Cutánea/efectos de los fármacos , Administración Cutánea , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Ciclohexenos/farmacología , Diclofenaco/administración & dosificación , Relación Dosis-Respuesta a Droga , Sinergismo Farmacológico , Cinética , Limoneno , Masculino , Ácido Oléico/farmacología , Técnicas de Cultivo de Órganos , Terpenos/farmacología , Urea/farmacologíaRESUMEN
This article reviews the general pharmacological properties of antimicrobial drugs used in feline medicine. It focuses on recent advances in pharmacokinetics, providing an update on indications, drug interactions and adverse reactions or toxicity in the cat. Attention is given to the most used groups, such as cephalosporins and fluoroquinolones, reviewing their basic features and clinical uses, and discusses the pharmacokinetic advantages of the newer members of each group. The older groups (penicillins, aminoglycosides, macrolides and tetracyclines) are also considered with regard to their general features and current uses, and any recent reports on adverse reactions in cats are provided.
Asunto(s)
Antibacterianos/administración & dosificación , Antibacterianos/uso terapéutico , Infecciones Bacterianas/veterinaria , Enfermedades de los Gatos/tratamiento farmacológico , Animales , Antibacterianos/farmacocinética , Infecciones Bacterianas/tratamiento farmacológico , GatosRESUMEN
The pharmacokinetic properties of ceftazidime, a third generation cephalosporin, were investigated in five cats after single intravenous (IV) and intramuscular (IM) administration at a dose rate of 30 mg/kg. Minimum inhibitory concentrations (MICs) of ceftazidime for some Gram-negative (Escherichia coli, n=11) and Gram-positive (Staphylococcus spp., n=10) strains isolated from clinical cases were determined. An efficacy predictor, measured as the time over which the active drug exceeds the bacteria minimum inhibitory concentration (T>MIC), was calculated. Serum ceftazidime disposition was best fitted by a bi-compartmental and a mono-compartmental open model with first-order elimination after IV and IM dosing, respectively. After IV administration, distribution was rapid (t(1/2(d)) 0.04+/-0.03 h), with an area under the ceftazidime serum concentration:time curve (AUC((0-infinity))) of 173.14+/-48.69 microg h/mL and a volume of distribution (V((d(ss)))) of 0.18+/-0.04 L/kg. Furthermore, elimination was rapid with a plasma clearance of 0.19+/-0.08 L/hkg and a t(1/2) of 0.77+/-0.06 h. Peak serum concentration (C(max)), T(max), AUC((0-infinity)) and bioavailability for the IM administration were 89.42+/-12.15 microg/mL, 0.48+/-0.49 h, 192.68+/-65.28 microg h/mL and 82.47+/-14.37%, respectively. Ceftazidime MIC for E. coli ranged from 0.0625 to 32 microg/mL and for Staphylococcus spp. from 1 to 64 microg/mL. T>MIC was in the range 35-52% (IV) and 48-72% (IM) of the recommended dosing interval (8-12h) for bacteria with a MIC(90)4 microg/mL.
Asunto(s)
Antibacterianos/farmacocinética , Gatos/metabolismo , Ceftazidima/farmacocinética , Animales , Antibacterianos/administración & dosificación , Ceftazidima/administración & dosificación , Estudios Cruzados , Femenino , Inyecciones Intramusculares/veterinaria , Inyecciones Intravenosas/veterinaria , MasculinoRESUMEN
The pharmacokinetic properties of ceftriaxone, a third-generation cephalosporin, were investigated in five cats after single intravenous, intramuscular and subcutaneous administration at a dosage of 25 mg/kg. Ceftriaxone MICs for some gram-negative and positive strains isolated from clinical cases were determined. Efficacy predictor (t > MIC) was calculated. Serum ceftriaxone disposition was best fitted by a bicompartmental and a monocompartmental open models with first-order elimination after intravenous and intramuscular and subcutaneous dosing, respectively. After intravenous administration, distribution was fast (t1/2d 0.14 +/- 0.02 h) and moderate as reflected by the volume of distribution (V(d(ss))) of 0.57 +/- 0.22 L/kg. Furthermore, elimination was rapid with a plasma clearance of 0.37 +/- 0.13 L/h.kg and a t1/2 of 1.73 +/- 0.23 h. Peak serum concentration (Cmax), tmax and bioavailability for the intramuscular administration were 54.40 +/- 12.92 microg/mL, 0.33 +/- 0.07 h and 85.72 +/- 14.74%, respectively; and for the subcutaneous route the same parameters were 42.35 +/- 17.62 microg/mL, 1.27 +/- 0.95 h and 118.28 +/- 39.17%. Ceftriaxone MIC for gram-negative bacteria ranged from 0.0039 to >8 microg/mL and for gram-positive bacteria from 0.5 to 4 microg/mL. t > MIC was in the range 83.31-91.66% (10-12 h) of the recommended dosing interval (12 h) for Escherichia coli (MIC90 = 0.2 microg/mL).
Asunto(s)
Antibacterianos/farmacocinética , Gatos/metabolismo , Ceftriaxona/farmacocinética , Animales , Antibacterianos/administración & dosificación , Antibacterianos/sangre , Área Bajo la Curva , Ceftriaxona/administración & dosificación , Ceftriaxona/sangre , Femenino , Bacterias Gramnegativas/efectos de los fármacos , Bacterias Grampositivas/efectos de los fármacos , Inyecciones Intramusculares/veterinaria , Inyecciones Intravenosas/veterinaria , Inyecciones Subcutáneas/veterinaria , Masculino , Pruebas de Sensibilidad MicrobianaRESUMEN
BACKGROUND: The arterial pharmacokinetics of ketamine and norketamine enantiomers after racemic ketamine or S-ketamine i.v. administration were evaluated in seven gelding ponies in a crossover study (2-month interval). METHODS: Anaesthesia was induced with isoflurane in oxygen via a face-mask and then maintained at each pony's individual MAC. Racemic ketamine (2.2 mg kg(-1)) or S-ketamine (1.1 mg kg(-1)) was injected in the right jugular vein. Blood samples were collected from the right carotid artery before and at 1, 2, 4, 8, 16, 32, 64, and 128 min after ketamine administration. Ketamine and norketamine enantiomer plasma concentrations were determined by capillary electrophoresis. Individual R-ketamine and S-ketamine concentration vs time curves were analysed by non-linear least square regression two-compartment model analysis using PCNonlin. Plasma disposition curves for R-norketamine and S-norketamine were described by estimating AUC, C(max), and T(max). Pulse rate (PR), respiratory rate (R(f)), tidal volume (V(T)), minute volume ventilation (V(E)), end-tidal partial pressure of carbon dioxide (PE'(CO(2))), and mean arterial blood pressure (MAP) were also evaluated. RESULTS: The pharmacokinetic parameters of S- and R-ketamine administered in the racemic mixture or S-ketamine administered separately did not differ significantly. Statistically significant higher AUC and C(max) were found for S-norketamine compared with R-norketamine in the racemic group. Overall, R(f), V(E), PE'(CO(2)), and MAP were significantly higher in the racemic group, whereas PR was higher in the S-ketamine group. CONCLUSIONS: Norketamine enantiomers showed different pharmacokinetic profiles after single i.v. administration of racemic ketamine in ponies anaesthetised with isoflurane in oxygen (1 MAC). Cardiopulmonary variables require further investigation.
Asunto(s)
Anestesia General/veterinaria , Anestésicos Combinados/sangre , Anestésicos Disociativos/sangre , Caballos/sangre , Ketamina/sangre , Anestesia General/métodos , Anestésicos Combinados/administración & dosificación , Anestésicos Combinados/farmacología , Anestésicos Disociativos/administración & dosificación , Anestésicos por Inhalación , Animales , Presión Sanguínea/efectos de los fármacos , Estudios Cruzados , Esquema de Medicación , Electrocardiografía , Frecuencia Cardíaca/efectos de los fármacos , Isoflurano , Ketamina/administración & dosificación , Ketamina/análogos & derivados , Masculino , Monitoreo Intraoperatorio/instrumentación , Monitoreo Intraoperatorio/métodos , Monitoreo Intraoperatorio/veterinaria , EstereoisomerismoRESUMEN
Pharmacokinetic and pharmacodynamic properties in goats of the non-steroidal anti-inflammatory drug tolfenamic acid (TA), administered both alone and in combination with the fluoroquinolone marbofloxacin (MB), were established in a tissue cage model of acute inflammation. Both drugs were injected intramuscularly at a dose rate of 2 mg kg(-1). After administration of TA alone and TA+MB pharmacokinetic parameters of TA (mean values) were Cmax=1.635 and 1.125 microg ml(-1), AUC=6.451 and 3.967 microgh ml(-1), t1/2K10=2.618 and 2.291 h, Vdarea/F=1.390 and 1.725Lkg(-1), and ClB/F=0.386 and 0.552 L kg(-1) h(-1), respectively. These differences were not statistically significant. Tolfenamic acid inhibited prostaglandin (PG)E2 synthesis in vivo in inflammatory exudate by 53-86% for up to 48 h after both TA treatments. Inhibition of synthesis of serum thromboxane (Tx)B2 ex vivo ranged from 16% to 66% up to 12h after both TA and TA+MB, with no significant differences between the two treatments. From the pharmacokinetic and eicosanoid inhibition data for TA, pharmacodynamic parameters after dosing with TA alone for serum TxB2 and exudate PGE2 expressing efficacy (Emax=69.4 and 89.7%), potency (IC50=0.717 and 0.073 microg ml(-1)), sensitivity (N=3.413 and 1.180) and equilibration time (t1/2Ke0=0.702 and 16.52 h), respectively, were determined by PK-PD modeling using an effect compartment model. In this model TA was a preferential inhibitor of COX-2 (COX-1:COX-2 IC50 ratio=12:1). Tolfenamic acid, both alone and co-administered with MB, did not affect leucocyte numbers in exudate, transudate or blood. Compared to placebo significant attenuation of skin temperature rise over inflamed tissue cages was obtained after administration of TA and TA+MB with no significant differences between the two treatments. Marbofloxacin alone did not significantly affect serum TxB2 and exudate PGE2 concentrations or rise in skin temperature over exudate tissue cages. These data provide a basis for the rational use of TA in combination with MB in goat medicine.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacocinética , Inhibidores Enzimáticos/farmacocinética , Fluoroquinolonas/farmacocinética , Cabras/metabolismo , Quinolonas/farmacocinética , ortoaminobenzoatos/farmacocinética , Animales , Antiinflamatorios no Esteroideos/sangre , Área Bajo la Curva , Estudios Cruzados , Dinoprostona/metabolismo , Interacciones Farmacológicas , Inhibidores Enzimáticos/sangre , Exudados y Transudados/metabolismo , Femenino , Fluoroquinolonas/sangre , Inflamación/tratamiento farmacológico , Leucocitos/efectos de los fármacos , Quinolonas/sangre , ortoaminobenzoatos/sangreRESUMEN
The pharmacokinetic properties of marbofloxacin, a third generation fluoroquinolone, were investigated in six cats after single intravenous (IV) and repeat oral (PO) administration at a daily dose of 2 mg/kg. Marbofloxacin serum concentration was analysed by microbiological assay using Klebsiella pneumoniae ATCC 10031 as micro-organism test. Serum marbofloxacin disposition was best described by bicompartmental and mono-compartmental open models with first-order elimination after IV and oral dosing respectively. After IV administration, distribution was rapid (T(1/2(d)) 0.23+/-0.24 h) and wide, as reflected by the steady-state volume of distribution of 1.01+/-0.15 L/kg. Elimination from the body was slow with a body clearance of 0.09+/-0.02 L/h kg and a T(1/2) of 7.98+/-0.57 h. After repeat oral administration, absorption half-life was 0.86+/-1.59 h and T(max) of 1.94+/-2.11 h. Bioavailability was almost complete (99+/-29%) with a peak plasma concentration at the steady-state of 1.97+/-0.61 mug/mL. Drug accumulation was not significant after six oral administrations. Calculation of efficacy predictors showed that marbofloxacin has good therapeutic profile against Gram-negative and Gram-positive bacteria with a MIC(50) value <0.25 microg/mL.
Asunto(s)
Antibacterianos/administración & dosificación , Antibacterianos/farmacocinética , Gatos , Fluoroquinolonas/administración & dosificación , Fluoroquinolonas/farmacocinética , Quinolonas/administración & dosificación , Quinolonas/farmacocinética , Administración Oral , Animales , Antibacterianos/sangre , Disponibilidad Biológica , Fluoroquinolonas/sangre , Inyecciones Intravenosas , Quinolonas/sangre , Estadística como AsuntoRESUMEN
The pharmacokinetic properties of the fluoroquinolone levofloxacin, were investigated in five cats after single intravenous and repeat oral administration at a daily dose of 10 mg/kg. Levofloxacin serum concentration was analyzed by microbiological assay using Klebsiella pneumoniae ATCC 10031 as test microorganism. Serum levofloxacin disposition after intravenous and oral dosing was best fitted to a bicompartmental and a monocompartmental open models with first-order elimination, respectively. After intravenous administration, distribution was rapid (t(1/2(d)) 0.26 +/- 0.18 h) and wide as reflected by the steady-state volume of distribution of 1.75 +/- 0.42 L/kg. Drug elimination was slow with a total body clearance of 0.14 +/- 0.04 L/h.kg and a t(1/2) for this process of 9.31 +/- 1.63 h. The mean residence time was of 12.99 +/- 2.12 h. After repeat oral administration, absorption half-life was of 0.18 +/- 0.12 h and Tmax of 1.62 +/- 0.84 h. The bioavailability was high (86.27 +/- 43.73%) with a peak plasma concentration at the steady state of 4.70 +/- 0.91 microg/mL. Drug accumulation was not significant after four oral administrations. Estimated efficacy predictors for levofloxacin after either intravenous or oral administration indicate a good profile against bacteria with a MIC value below of 0.5 microg/mL. However, for microorganisms with MIC values of 1 microg/mL it would be efficacious only when administered intravenously.
Asunto(s)
Antibacterianos/farmacocinética , Gatos/metabolismo , Levofloxacino , Ofloxacino/farmacocinética , Administración Oral , Animales , Antibacterianos/administración & dosificación , Antibacterianos/sangre , Antibacterianos/farmacología , Área Bajo la Curva , Esquema de Medicación , Femenino , Inyecciones Intravenosas/veterinaria , Klebsiella pneumoniae/efectos de los fármacos , Masculino , Pruebas de Sensibilidad Microbiana , Ofloxacino/administración & dosificación , Ofloxacino/sangre , Ofloxacino/farmacologíaRESUMEN
Body temperature responses and the timing of abortions were evaluated in pregnant bitches with the anti-progestin aglepristone. Fifteen purebred and crossbred, 25-45 days pregnant, were included in this study and seven untreated bitches at the same stage of pregnancy served as controls. Treated bitches were administered two applications of aglepristone (10 mg/kg SC) 24 h apart for pregnancy termination. Pregnancy termination was confirmed by ultrasonographic assessment. Body temperature was rectally measured three times a day for 6 days beginning 24 h before treatment or pregnancy diagnosis in the treated and control bitches, respectively. Additionally, serum progesterone concentrations were assessed at time points during the study in the treated bitches. Pregnancy was terminated in 14 treated bitches in a mean+/-S.E.M. of 4.3+/-0.7 days after treatment. Control bitches remained pregnant. In the treated bitches, but not in the controls, body temperature significantly decreased 24 h after the beginning of the treatments (P < 0.01) and then gradually returned to pre-treatment values. Correlation between the day of mean minimum body temperature and the day of pregnancy termination was low (0.07; > 0.05). Progesterone did not show significant change throughout the study. Body temperature does not seem to be a suitable variable to clinically monitor the aborting effect of aglepristone. Decrease of body temperature after aglepristone treatment could represent further evidence of its hypothalamic effects.